Incyte Corp. could achieve label expansion with the already successful myelofibrosis (MF) drug Jakafi (ruxolitinib) by the end of this year, thanks to a phase III victory in the myeloproliferative neoplasm known as polycythemia vera (PV), which sometimes advances to MF.